.png)
At Shivanka, we lead the way in creating innovative therapies for unmet needs in oncology and rare diseases. With a legacy of excellence in research, we leverage validated small-molecule scaffolds to unlock novel mechanisms and efficiently advance assets from early discovery to the first-in-human trials.
Shivanka is a distinguished drug discovery company specialized in the discovery of therapeutic interventions targeting prevalent human ailments, backed by a highly experienced team and a parent company with a strong track record in innovation.
.png)
With a strong focus on oncology, our efforts emphasize developing treatments for cancers that are resistant to conventional therapies, such as ER+/HER2- breast cancer. We are dedicated to providing innovative solutions that can improve the lives of patients with critical unmet need.
In addressing the critical needs in women's health, we concentrate on conditions such as interstitial cystitis and breast cancer. Our products are designed to significantly enhance the quality of life for women suffering from these debilitating conditions.
.png)
At the forefront of treatment development for rare diseases, our pipeline includes innovative therapies for orphan conditions where current options are limited. We are committed to advancing care for those who face these challenging conditions.
The Shivanka team is composed of high-level experts with decades of combined experience in the research, development, and commercialization of innovative therapies. With a comprehensive focus on women's health and rare diseases, our team has demonstrated the ability to take products from discovery to approval and commercialization. We collaborate closely and effectively, leveraging our diverse expertise to deliver unique and highly effective therapeutic solutions.
Designed to improve bioavailability and efficacy in the treatment of advanced ER+/HER2- breast cancer. Currently in Phase 1 clinical trials, it has shown promising results from preclinical studies and initial human trials.
Targeting patients with advanced ER+/HER2- breast cancer, this oral antagonist has demonstrated strong efficacy in preclinical models and is advancing toward Phase 1b/2 clinical trials.
Developed to address interstitial cystitis and bladder pain, this innovative treatment is in preclinical development and holds the potential to redefine the standard of care for IC/BPS patients.
SHRN3 aims to achieve sustained Levodopa levels by reducing "off time", minimizing dosing frequency and improving quality of life of Parkinson's disease patients.
Sublingual delivery resulted in reduced first-pass metabolism, dose reduction, potentially lowering cost, minimizing drug interactions and GI issues. Advancing with Phase III trial in adult and adolescent Gaucher Disease Type-I patients.
Latest Resources
Enhancing access to treatment for Gaucher disease in India: The need for indigenous manufacturing.
Preclinical characterization of SHRN1126, a novel, differentiated and steroidal oral selective estrogen receptor degrader (SERD).
Pharmacological Profiling of KSHN001034 – A novel prodrug of Fulvestrant with improved efficacy.
If you have any questions or need more information, don't hesitate to get in touch with us.
Address
USA
Shivanka Research, LLC
400 Crossings Blvd.
3rd Floor Bridgewater, NJ 08807
India
Shivanka Research Pvt. Ltd.
(A wholly owned subsidiary of Shivanka Research, LLC)
27/2 & 43, Mauje Sarkhej, BK B Paiki
Opp. Applewood, Sarkhej, Ahmedabad,
Sanand, Gujarat, India, 382210
Phone
(XXX) XXX XXX direct
(XXX) XXX XXX fax
.png)